Gordian Capital Singapore Pte Ltd grew its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 400.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,000 shares of the conglomerate's stock after purchasing an additional 5,600 shares during the period. Danaher makes up about 0.8% of Gordian Capital Singapore Pte Ltd's portfolio, making the stock its 28th biggest holding. Gordian Capital Singapore Pte Ltd's holdings in Danaher were worth $1,607,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund boosted its stake in Danaher by 11.6% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate's stock worth $4,874,000 after purchasing an additional 2,202 shares in the last quarter. FAS Wealth Partners Inc. raised its holdings in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after buying an additional 1,639 shares during the last quarter. Generate Investment Management Ltd acquired a new stake in shares of Danaher during the fourth quarter worth $8,044,000. Compass Capital Management Inc. grew its holdings in shares of Danaher by 4.8% during the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate's stock valued at $54,615,000 after buying an additional 10,994 shares during the last quarter. Finally, Channing Global Advisors LLC increased its position in shares of Danaher by 42.8% in the 4th quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate's stock valued at $1,301,000 after acquiring an additional 1,698 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. This represents a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.
Danaher Price Performance
DHR stock opened at $186.50 on Thursday. The business's fifty day moving average price is $196.07 and its 200 day moving average price is $216.57. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70. The company has a market capitalization of $133.47 billion, a PE ratio of 35.32, a P/E/G ratio of 2.66 and a beta of 0.80. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.
Danaher Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.69%. Danaher's dividend payout ratio is presently 24.85%.
Analysts Set New Price Targets
A number of brokerages have recently commented on DHR. UBS Group lowered their target price on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird dropped their price objective on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. dropped their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 22nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $263.24.
View Our Latest Report on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
